09:21 AM EST - Oncolytics Biotech Inc : Today highlighted clinical and translational data from three metastatic colorectal cancer ("mCRC") studies demonstrating consistent efficacy signals, immune activation, and survival outcomes that exceed historical benchmarks in multiple mCRC treatment settings. Oncolytics Biotech Inc
shares N.ONCY are trading off $0.02 at $1.06.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=6645085435162788
